|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-9-17
|
|
pubmed:abstractText |
Nedaplatin is a second-generation platinum showing favorable activity against non-small cell lung cancer (NSCLC). Dose-limiting toxicity (DLT) is thrombocytopenia, predicted by creatinine clearance (Ccr). This study was conducted to determine the recommended dose, and evaluate the toxicities, pharmacokinetics and efficacy for elderly NSCLC patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
79-88
|
|
pubmed:meshHeading |
pubmed-meshheading:19396598-Aged,
pubmed-meshheading:19396598-Aged, 80 and over,
pubmed-meshheading:19396598-Antineoplastic Agents,
pubmed-meshheading:19396598-Area Under Curve,
pubmed-meshheading:19396598-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:19396598-Carcinoma, Squamous Cell,
pubmed-meshheading:19396598-Creatinine,
pubmed-meshheading:19396598-Dose-Response Relationship, Drug,
pubmed-meshheading:19396598-Female,
pubmed-meshheading:19396598-Humans,
pubmed-meshheading:19396598-Kidney Function Tests,
pubmed-meshheading:19396598-Leukopenia,
pubmed-meshheading:19396598-Lung Neoplasms,
pubmed-meshheading:19396598-Male,
pubmed-meshheading:19396598-Maximum Tolerated Dose,
pubmed-meshheading:19396598-Neutropenia,
pubmed-meshheading:19396598-Organoplatinum Compounds,
pubmed-meshheading:19396598-Thrombocytopenia
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
|
|
pubmed:affiliation |
Division of Internal Medicine, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan. nbryamam@ncc.go.jp
|
|
pubmed:publicationType |
Journal Article,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|
